← boardnext 2026-10next 2027-08next 2027-08
CRNX
Crinetics Pharmaceuticals Inc.distress 1/10 · well-funded / low risk$83.670%today0% from 52w high
Nephrology 1
Lead: Congenital Adrenal Hyperplasia · target ACTH/MC2R
Revenue
$11M
Liquidity
$1291M
Runway
3.1 yrs
Shares 1y
+12%
Price & events
+52.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.1%
1D
-0.3%
1W
+133.0%
1M
+117.3%
3M
+57.3%
6M
+170.1%
1Y
+52.6%
2Y
+318.7%
5Y
+499.7%
All
Overview
- Market Cap
- $8.82B
- Volume
- 793.07K
- 52 Week Range
- $26.85 – $83.91
- Total Shares
- 105.44M
- Float Shares
- 95.55M
- Short %
- 15.38%
- % Held by Insiders
- 1.59%
- % Held by Institutions
- 119.81%
- RVOL
- 0.13x
- Beta
- 0.23
Pipeline stages · 3 programs
Atumelnant
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Paltusotine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
CRN09682
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 9 trials · 7 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-10 Estimated 50% readout ~2026-11-15 | Phase 1/2 | atumelnant | Cushing Syndrome, Cushing Disease, Ectopic ACTH Syndrome | — | recruiting |
| 2027-05 Estimated 50% readout ~2027-07-15 | Phase 3 | Atumelnant | Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia | — | recruiting |
| 2027-08 Estimated 50% readout ~2027-09-15 | Phase 1/2 | CRN09682 | SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors, Neuroendocrine Neoplasm | — | recruiting |
| 2027-08 Estimated 50% readout ~2027-10-15 | Phase 3 | Paltusotine | Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum, Carcinoid Tumor of Cecum, Carcinoid Tumor of Liver, Carcinoid Tumor of Pancreas, Carcinoid Syndrome Diarrhea, Carcinoid Intestine Tumor | — | recruiting |
| 2028-03 Estimated 50% readout ~2028-04-15 | Phase 2 | Paltusotine | Acromegaly | — | active not recruiting |
Show all 9 trials · 4 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2029-07 Estimated 50% readout ~2029-08-15 | Phase 2 | atumelnant (CRN04894) | Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia | — | recruiting |
| 2030-03 Estimated 50% readout ~2030-05-15 | Phase 2/3 | Atumelnant | Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia | — | recruiting |
| 2026-02-07 | Phase 1 | Atumelnant | Healthy Volunteers | 21 | completed |
| 2025-08-22 | Phase 2 | atumelnant (CRN04894) | Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia | 38 | completed |
Catalyst news & presentations · 9
- 2026-08-04Confirmed 100%earningsEarningsEarnings releaseyahoo
- first half of 2026chmp opinionCHMP (EU)paltusotine · MAA under review; CHMP opinion expected in first half of 2026SEC 8-K
- January 5, 2026readoutPhase 2atumelnant · Topline results from fourth cohort of Phase 2 trial; met endpoints for androstenedione reduction and glucocorticoid dose reduction.SEC 8-K
- 2025trial initiationsecondaryatumelnant · Later-stage trial initiation for Cushing's disease patientsSEC 8-K
- September 25, 2025PDUFAPDUFApaltusotine · PDUFA target action date for NDA reviewSEC 8-K
- 12:00-1:30 PMconferencedata presentationsecondaryPhase 3paltusotine · Poster on PATHFNDR-2 open-label extension interim resultsSEC 8-K
- 12:00-1:30 PMconferencedata presentationsecondaryPhase 2atumelnant · Poster on reduction of 11-oxygenated androgensSEC 8-K
- first half of 2025trial initiationsecondaryPhase 3atumelnant · Phase 3 initiation for adult CAH patientsSEC 8-K
- January 14, 2025 at 4:30 pm PTconferencedata presentationsecondaryCompany update at 43rd J.P. Morgan Healthcare ConferenceSEC 8-K
Approved drugs (1)
- PALSONIFYPALTUSOTINE HYDROCHLORIDE2025 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
hold · target $83 (-1% upside) · 10 analysts
- 2026-07-08Evercore ISI GroupOutperform → In-Line
- 2026-07-08TD CowenBuy → Hold
- 2026-07-07OppenheimerOutperform → Perform
- 2026-07-07JefferiesBuy → Hold
- 2026-07-07HC Wainwright & Co.Buy → Neutral
- 2026-07-07Cantor FitzgeraldOverweight → Neutral
Competitors — ACTH/MC2R
- none identified
Recent news
- 2026-07-22What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunit - Benzinga
- 2026-07-22How Crinetics Pharmaceuticals Inc. (CRNX) Affects Rotational Strategy Timing - Stock Traders Daily
- 2026-07-22Vertex-Crinetics Pharmaceuticals deal faces Australian review - MLex
- 2026-07-22Crinetics Pharmaceuticals (CRNX) Piper Sandler 36th Annual Healthcare Conference summary - Quartr
- 2026-07-21CRNX: Pipeline advances in acromegaly, CAH, and NETs, with strong financial runway into 2030 - TradingView
- 2026-07-21Shareholder Alert: Ademi LLP investigates whether Crinetics - GlobeNewswire
- 2026-07-20Crinetics Pharmaceuticals (CRNX) Q2 2025 earnings summary - Quartr
- 2026-07-20Crinetics Pharmaceuticals (CRNX) R&D Day 2025 Summary - Quartr
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.